Mankind Pharma Acquires Rivotril Brand for Indian CNS Market
Filing Summary
Mankind Pharma Limited has acquired the Rivotril brand from Roche for the Indian market. This acquisition grants Mankind Pharma exclusive rights to manufacture, market, and distribute Rivotril, a clonazepam-based product, across India. The move aligns with the company’s strategic focus on expanding its presence in the chronic and central nervous system (CNS) therapy segments. Mankind Pharma aims to leverage its extensive distribution network and field force to enhance access to Rivotril. The acquisition is part of Mankind Pharma’s broader strategy to strengthen its portfolio in chronic therapies.
Mankind Pharma Limited has announced the acquisition of the Rivotril brand from Roche for the Indian market. This acquisition provides Mankind Pharma with exclusive rights to manufacture, market, and distribute Rivotril across India. Rivotril, known for its clonazepam formulation, is widely prescribed for neurological and psychiatric conditions. The acquisition is part of Mankind Pharma’s strategy to enhance its presence in the central nervous system (CNS) therapy segment.
The financial terms of the acquisition have not been disclosed in the filing. However, the acquisition is expected to integrate into Mankind Pharma’s existing operations without any immediate financial restructuring. The company has not specified any payment structures or financial milestones related to this acquisition.
Operationally, Mankind Pharma will leverage its extensive distribution network and large field force to support the wider access to Rivotril across healthcare institutions and prescribers in India. The company engages with over 500,000 doctors and has a significant prescription share in the Indian pharmaceutical market. This acquisition is expected to complement Mankind Pharma’s existing neuro portfolio and expand treatment options for patients managing neurological conditions.
The acquisition of Rivotril aligns with Mankind Pharma’s strategic focus on chronic therapies, where the company has been expanding its presence through new launches, in-licensing partnerships, and portfolio additions. Chronic therapies now account for a growing share of the company’s overall business. The addition of Rivotril, a brand with strong clinical legacy and specialist recall, is expected to enhance Mankind Pharma’s CNS portfolio.
The timeline for the integration of Rivotril into Mankind Pharma’s operations has not been specified in the filing. However, the company plans to utilize its nationwide distribution network to ensure the product’s availability across urban and semi-urban markets in India. The acquisition does not involve any additional parties or collaborations.
Mankind Pharma is one of the largest pharmaceutical companies in India, focusing on the domestic market with a pan-India presence. The company operates at the intersection of pharmaceutical formulations and consumer healthcare sectors, providing quality products at affordable prices. Mankind Pharma is a leading player in both acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, and respiratory segments. The company continues to expand its chronic therapy portfolio and strengthen its leadership in the domestic pharmaceuticals market.